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Abstract: The influence of membrane microviscosity on
m-opioid agonist and antagonist binding, as well as ag-
onist efficacy, was examined in membranes prepared
from SH-SY5Y cells and from a C6 glioma cell line stably
expressing the rat m-opioid receptor (C6m). Addition of
cholesteryl hemisuccinate (CHS) to cell membranes in-
creased membrane microviscosity and reduced the in-
hibitory effect of sodium and guanine nucleotides on the
affinity of the full agonists sufentanil and [D-Ala2,N-
MePhe4,Gly-ol5]enkephalin (DAMGO) for the m-opioid re-
ceptor. Binding of the antagonists [3H]naltrexone and
[3H]diprenorphine and the partial agonist nalbuphine was
unaffected by CHS. The effect of CHS on agonist binding
was reversed by subsequent addition of cis-vaccenic
acid, suggesting that the effect of CHS is the result of
increased membrane microviscosity and not a specific
sterol–receptor interaction. CHS addition increased the
potency of DAMGO to stimulate guanosine-59-O-(3-
[35S]thio)triphosphate binding by fourfold, whereas the
potency of nalbuphine was unaffected. However, nalbu-
phine efficacy relative to that of the full agonist DAMGO
was strongly increased in CHS-treated membranes com-
pared with that in control membranes. Membrane rigidi-
fication also resulted in an increased efficacy for the
partial agonists meperidine, profadol, and butorphanol
relative to that of DAMGO as measured by agonist-stim-
ulated GTPase activity in control and CHS-modified
membranes. These findings support a regulatory role for
membrane microviscosity in receptor-mediated G protein
activation. Key Words: Opioid receptor—Opioid ago-
nists—Efficacy—Membrane fluidity—Cholesterol.
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Alterations in membrane lipid composition and bio-
physical properties may provide potential mechanisms
by which a cell can regulate the function of integral
membrane proteins. Protein function may be regulated
by the direct binding of phospholipid, ionic headgroups,
and hydrophobic acyl chains or through binding of cho-
lesterol to the transmembrane domains (Fong and Mc-
Namee, 1987; Selinsky, 1992). Changes in lipid compo-
sition may also regulate protein function and protein–
protein interactions through effects on membrane
biophysical properties such as microviscosity, thus po-
tentially affecting protein lateral diffusion or protein
conformational changes (Stubbs and Smith, 1984;
Yeagle, 1991; Selinsky, 1992). For example, the function
of receptors coupled to adenylyl cyclase and possibly the
enzyme itself are sensitive to alterations in membrane
fluidity (Hanski et al., 1979; Depauw et al., 1990).
Determination of the lipid requirements for reconsti-
tution of functional opioid (Hasegawa et al., 1987;
Scheideler and Zukin, 1990),b-adrenergic (Ben-Arie et
al., 1988), and muscarinic acetylcholine (Berstein et al.,
1989) receptors illustrates the importance of specific
interactions between these receptors and the lipid bilayer
(Fong and McNamee, 1987). Also, the influence of mem-
brane biophysical properties, e.g., lipid packing and mo-
bility, on opioid receptor binding (Heron et al., 1981;
Remmers et al., 1990; Lazar and Medzihradsky, 1992)
and metarhodopsin conformational changes (Mitchell et
al., 1992, 1996) illustrates the role of the membrane
bilayer as a regulator of protein flexibility. Alterations in
membrane microviscosity or composition have also been
shown to modulate opioid receptor-mediated signal
transduction (Abood et al., 1978; Law et al., 1983; Lazar
and Medzihradsky, 1989).
Ligand binding affinity for the opioid receptor is an
indicator of receptor conformation. The binding of opi-
oid ligands is modulated by addition of sodium and
guanine nucleotides (Blume, 1978; Ott and Costa, 1988).
High-affinity binding of agonists to the receptor requires
the association of receptor with G protein (Remmers and
Medzihradsky, 1991a), and addition of sodium or gua-
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nine nucleotides dissociates this complex to convert the
receptor to a conformation with low affinity for agonist
(Blume, 1978; Childers and Snyder, 1980; Ott and Costa,
1988). In contrast, antagonist binding is increased by
sodium and unchanged by further addition of guanine
nucleotides, indicating an insensitivity to the presence of
G protein (Simantov et al., 1976; Childers and Snyder,
1980; Nijssen and Childers, 1987). We have shown that
rigidification of rat brain membranes reduced the effect
of sodium on both opioid agonist and antagonist binding,
suggesting that membrane biophysical properties can
alter the sodium-induced conformational transitions of
the m-opioid receptor (Lazar and Medzihradsky, 1993).
However, these experiments did not address receptor-
mediated G protein activation in membranes with re-
duced fluidity.
In the current study, we have examined the effect of
membrane rigidification onm-opioid agonist binding and
G protein activation in membranes from the SH-SY5Y
neuroblastoma cell line and from a C6 glioma cell line
stably expressing the ratm-opioid receptor (C6m) (Em-
merson et al., 1996). Although the effects of temperature
and GDP on agonist efficacy have been evaluated
(Lorenzen et al., 1996; Breivogel et al., 1998), to our
knowledge the potential modulatory role of membrane
fluidity on agonist efficacy has never been evaluated. The
results presented suggest that membrane microviscosity
can modulate specific agonist-sensitive conformational
changes in the absence of any effect on antagonist bind-
ing. Membrane microviscosity also modulates the effi-
cacy of opioid agonists, further supporting a regulatory
role for the lipid bilayer in opioid agonist binding and
signal transduction. A preliminary report of this study
was presented previously (Emmerson et al., 1994).
MATERIALS AND METHODS
Materials
[3H]Sufentanil was purchased from Research Diagnostics




([3H]DAMGO) were from Amersham Co. (Arlington Heights,
IL, U.S.A.), and [3H]naltrexone and [3H]diprenorphine were
obtained from the National Institute on Drug Abuse.
[g-32P]GTP and guanosine-59-O-(3-[35S]thio)triphosphate
([35S]GTPgS) were obtained from Du Pont-NEN (Wilmington,
DE, U.S.A.). DAMGO, cholesteryl hemisuccinate (CHS), Dul-
becco’s modified Eagle’s medium, GTPgS, andN-ethylmale-
imide (NEM) were purchased from Sigma Chemical Co. (St.
Louis, MO, U.S.A.). All other unlabeled opioids were supplied
by the Narcotic Drug and Opiate Peptide Basic Research Cen-
ter at the University of Michigan. Pertussis toxin (PTX) was
purchased from List Biochemicals (Campbell, CA, U.S.A.).
Fetal bovine serum was from GIBCO Life Sciences (Gaithers-
burg, MD, U.S.A.). cis-Vaccenic acid was purchased from
Serdary Research Laboratories (London, Ontario, Canada).
Diphenylhexatriene (DPH) and trimethylammonium-DPH
(TMA-DPH) were obtained from Molecular Probes (Eugene,
OR, U.S.A.). Human neuroblastoma SH-SY5Y cells, originat-
ing from Dr. June L. Biedler (Memorial Sloan-Kettering Can-
cer Center, New York, NY, U.S.A.), were a generous gift from
Dr. S. K. Fisher (Department of Pharmacology, University of
Michigan).
Cell culture
SH-SY5Y cells (passages 76–100) were grown for 8–10
days in Dulbecco’s modified Eagle’s medium containing 10%
fetal bovine serum in tissue culture flasks under a 10% CO2
atmosphere at 37°C. Medium was partially replaced every third
day. PTX treatment was carried out by incubating the cells with
50 ng/ml for 24 h at 37°C in culture flasks. C6m cells (Em-
merson et al., 1996) were grown under 5% CO2 in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum
and 1 mg/ml geneticin.
Membrane preparation
Cells were washed three times with ice cold phosphate-
buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, and 0.38 mM
KH2PO4, pH 7.4) and incubated with modified Ca
21/Mg21-
free Pucks buffer to dissociate the cells (Carter and Medzihrad-
sky, 1992). The cell suspension was pelleted by centrifugation
for 3 min at 300g. Nuclei were removed by resuspending the
cells in 10 volumes of ice-cold hypotonic phosphate buffer
(0.61 mM Na2HPO4, 0.38 mM KH2PO4, and 0.2 mM MgSO4,
pH 7.4 at 4°C) using a Dounce all-glass tissue homogenizer
followed by centrifugation for 10 min at 500g and 4°C.
Membranes were collected by centrifuging the supernatant for
20 min at 20,000g and 4°C and resuspended in Tris buffer (50
mM, pH 7.4). Membranes from C6m cells were prepared by
lysis in 0.32M sucrose as previously described (Emmerson et
al., 1996). All membranes were suspended in Tris buffer, and
aliquots at 2 mg/ml were frozen at280°C until used.
NEM treatment of membranes
Alkylation of G protein by NEM was accomplished under
conditions that protect the activity of them-opioid receptor as
described earlier (Tocque et al., 1987). Membranes (1–2 mg of
protein/ml) were incubated in Tris buffer for 30 min at 25°C
with 50 nM naltrexone and 3 mM NaCl. Subsequently, 5 mM
NEM was added, and the solution was incubated for an addi-
tional 2 h. The reaction was terminated by addition of an equal
volume of ice-cold Tris buffer and centrifugation for 15 min at
20,000 g. Membranes were washed by resuspension in Tris
buffer and centrifugation. To remove residual naltrexone and
NaCl, the pellet was resuspended in Tris buffer and incubated
for 30 min at 25°C followed by two additional washes of the
membranes. The final pellet was resuspended in Tris buffer,
and individual aliquots were frozen at280°C. Inactivation of
the m-opioid receptor was determined by comparison of the
loss in specific opioid agonist and antagonist binding.
CHS and cis-vaccenic modification of membranes
CHS andcis-vaccenic acid were added as a solution in
ethanol to membranes suspended in Tris buffer (25°C, 50 mM,
pH 7.4) with vigorous mixing. Control membranes were incu-
bated with a corresponding volume of ethanol. After incubation
for 30 min at 25°C, the mixture was centrifuged for 15 min at
20,000g and 4°C, and the pellet was resuspended in Tris buffer
using a Dounce homogenizer. CHS incorporation was deter-
mined following lysis of the succinate ester by incubation of
cell membranes and standards with 2.5M KOH for 30 min at
25°C. After neutralization with 2.5M HCl, total cholesterol
content was determined by an enzymatic-fluorometric proce-
dure (Heider and Boyett, 1978). Recovery of CHS was.95%.
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Measurement of membrane microviscosity
The fluorescent probe DPH or its cationic derivative TMA-
DPH (0.3mM) was incubated for 45 min at 25°C with mem-
branes (50–100mg of protein). Fluorescence anisotropy was
measured with a Spex FluoroMax spectrofluorometer using
excitation and emission wavelengths of 340 and 450 nm, re-
spectively. The results were expressed as anisotropy values (r),
wherer 5 (I0 2 I90)/(I0 2 2I90) and I0 and I90 represent the
intensities of light when light polarizing filters were in a par-
allel and perpendicular orientation, respectively.
Quantification of protein
Membranes were initially digested with 1M NaOH for 45
min at 25°C. Protein was then analyzed by the method of
Lowry et al. (1951) with bovine serum albumin as a standard.
Stimulation of low-Km GTPase activity
Basal and opioid stimulated low-Km GTPase activities were
determined as previously described (Clark et al., 1989) with the
following modifications. Membranes were preincubated in the
same buffer used for the [35S]GTPgS binding assay [50 mM
Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl2, 1 mM EDTA,
and 1 mM dithiothreitol] for 10 min with 10mM GDP in the
absence or presence of agonist, followed by addition of 1 nM
[g-32P]GTP. Following a 10-min incubation at 37°C, the reac-
tion was terminated by addition of a slurry of charcoal and
phosphoric acid followed by centrifugation. The free32P re-
maining in the supernatant was quantified by liquid scintillation
counting.
Stimulation of [35S]GTPgS binding
Agonist stimulation of [35S]GTPgS binding was measured
as described previously (Emmerson et al., 1996). C6m cell
membranes (5mg per tube) were preincubated with ligand for
10 min at 25°C. The experiment was initiated by addition of
[35S]GTPgS binding assay buffer to yield a final concentration
in 100 ml of 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM
MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 50mM GDP, and 50
pM [35S]GTPgS. Tubes were incubated for 30 min at 25°C, and
the reaction was terminated by diluting the sample with 2 ml of
ice-cold Tris buffer containing 5 mM MgCl2 and 100 mM NaCl
and rapidly filtering the tube contents through glass fiber filters
(no. 32; Schleicher and Schuell, Keene, NH, U.S.A.). The
filters were then washed an additional three times with 2 ml of
buffer. Filters were placed in vials containing 0.4 ml of ethanol
and 4 ml of scintillation cocktail for liquid scintillation count-
ing. Basal activity was defined by the difference between the
[35S]GTPgS binding in the absence or presence of 50mM
GTPgS.
Ligand binding
Equilibrium ligand binding to SH-SY5Y and C6m mem-
branes was determined as previously described (Carter and
Medzihradsky, 1992; Emmerson et al., 1996). In brief, assay
tubes containing 15–50mg of membrane protein in Tris buffer
were incubated with NaCl (150 mM) or NaCl (150 mM) plus
GTPgS (1mM) for 15 min at 25°C. Subsequently, radioligand
was added, and the tubes were incubated at 25°C to equilibrium
(60 min for [3H]naltrexone and [3H]diprenorphine, 80 min for
[3H]DAMGO, and 120 min for [3H]sufentanil). Specific bind-
ing of the radioligand was determined in the absence and
presence of excess (1mM) unlabeled ligand. Binding of [3H]-
naltrexone and [3H]diprenorphine tod-opioid receptors in SH-
SY5Y membranes was suppressed by inclusion of 50 nM
oxymorphindole to the assay (Remmers and Medzihradsky,
1991b). Samples were filtered through Schleicher and Schuell
no. 32 glass fiber filters presoaked for 30 min in 0.05% poly-
ethylenimine (pH 7.4), mounted in a Brandel 24-well cell
harvester, and washed four times with ice-cold Tris buffer.
Ethanol (0.4 ml) and scintillation fluid (4 ml) were added to the
filters, and the samples were subjected to liquid scintillation
counting.
Data analysis
Saturation binding data were pooled from three or four
experiments and compared with one-site, one-site plus a non-
saturable linear component, and two-site saturation models by
nonlinear regression analysis using the NONLIN module of the
computer program SYSTAT (Wilkenson, 1988) as described
earlier (Carter and Medzihradsky, 1992). The best-fit model
was determined using theF-ratio test to compare the weighted
residual sum of squares withp , 0.05. [35S]GTPgS binding
curves were fit to sigmoidal curves, and radioligand displace-
ment curves were fit using one- versus two-site competition
models using Graph Pad Prism (GraphPad, San Diego, CA,
U.S.A.). All t tests performed were two-tailed and unpaired.
RESULTS
Modulation of SH-SY5Y membrane microviscosity
The initial results presented here (Fig. 1) confirm the
effects of added cholesterol on agonist binding observed
in rat brain membranes (Heron et al., 1981; Lazar and
Medzihradsky, 1993). CHS rigidification of SH-SY5Y
membranes was examined using both nonpolar DPH and
cationic TMA-DPH fluorescent membrane probes. The
polarized fluorescence of these probes reflects membrane
microviscosity at the core and surface of the membrane,
respectively. Addition of CHS (0.5–2.75mmol/mg of
membrane protein) increased both DPH and TMA-DPH
fluorescence anisotropy (Fig. 1A). CHS addition dramat-
ically increased the microviscosity at the core of the
membrane (45%), whereas the increase at the surface
was limited (11%). Quantification of the levels of CHS
incorporated into the membrane showed that.90% of
added CHS was retained in the membrane at 0.45mmol
of added CHS/mg of protein and 80% at 2.4mmol of
added CHS/mg of protein. Addition of CHS increased
the total membrane cholesterol content by;60 and
590% at 0.45 and 2.4mmol of CHS added/mg of mem-
brane protein, respectively. No change in membrane
protein was found on CHS addition (data not shown). To
distinguish between the effects of CHS-mediated
changes in membrane microviscosity versus specific ste-
rol–protein interactions, the effects of CHS on membrane
microviscosity were reversed by addition of a potent
fluidizing fatty acid,cis-vaccenic acid (Remmers et al.,
1990). Following CHS addition (2mmol/mg of protein),
addition of cis-vaccenic acid reversed the change in
TMA-DPH anisotropy by 95% and that of DPH by 61%,
indicating a reversal of the CHS rigidification of the
surface and core of the membrane (Fig. 1A, inset).
Opioid binding in control and CHS-modified
membranes
Following modification with CHS, the binding of opi-
oid agonists and antagonists was examined. CHS addi-
tion selectively modulated the inhibitory effect of so-
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dium and guanine nucleotides on agonist binding to the
opioid receptor in SH-SY5Y membranes. Addition of
CHS did not significantly alter [3H]sufentanil binding in
the absence of sodium and GTPgS (Fig. 1B). The most
striking effect of CHS was the reduced inhibition of
sufentanil binding by sodium and guanine nucleotide. In
unmodified membranes, 0.1 nM [3H]sufentanil binding
was reduced by addition of sodium and to a greater
extent by both sodium and GTPgS. Increasing concen-
trations of CHS strongly reduced the inhibitory effect of
sodium and GTPgS. At high concentrations of CHS
(2.76mmol/mg of protein), the reduction of agonist bind-
ing by sodium was completely abolished, and that by the
combination of sodium and GTPgS was greatly reduced.
In contrast to sufentanil binding, CHS addition slightly
decreased DAMGO (1 nM) binding in the absence of
sodium and also reduced the modulatory effect of so-
dium (Fig. 2A), although to a lesser extent than for
sufentanil binding. This suggests that the effects of CHS
on agonist binding may be determined, in part, by some
characteristic of the ligand. In contrast to the effect of
sodium on antagonist binding in rat brain membranes
(Lazar and Medzihradsky, 1993), the binding of the
antagonist [3H]naltrexone was insensitive to addition of
NaCl in membranes from SH-SY5Y cells (Fig. 2A).
Also, addition of CHS had no effect on the binding of
naltrexone in the presence of 150 mM NaCl and only
slightly decreased naltrexone binding in the absence of
NaCl (Fig. 2A). Also, at high concentrations of CHS, no
loss in antagonist binding or membrane protein content
was found. These findings suggest that the effects of
membrane rigidification were mediated through agonist-
sensitive conformational changes in the receptor and not
FIG. 2. Opioid agonist and antagonist binding in control and
CHS-modified SH-SY5Y membranes. SH-SH5Y membranes
were modified with 2.5 mmol of CHS/mg of protein as described
in Materials and Methods. A: The specific binding of [3H]DAMGO
(1.0 nM ) and [3H]naltrexone (2.0 nM ) in the absence (open col-
umns) and presence (solid columns) of NaCl (150 mM ) was
measured. B: Membranes were pretreated with NEM as de-
scribed in Materials and Methods followed by CHS addition.
[3H]Sufentanil binding (0.1 nM ) was measured in control (left)
and alkylated (right; 1 NEM) membranes in the absence (open
columns) and presence (solid columns) of 150 mM NaCl. C: Cells
in culture were incubated with PTX (50 ng/ml) for 24 h, mem-
branes were prepared, and CHS was added. [3H]Sufentanil bind-
ing (0.1 nM ) was measured in control (left) and toxin-treated
(right; 1 PTX) membranes in the absence (open columns) and
presence (solid columns) of 150 mM NaCl and 10 mM GTPgS.
Data are mean 6 SEM (bars) values from three experiments,
each carried out in duplicate. *p , 0.01, significant differences
between the pairwise comparisons indicated by the bars.
FIG. 1. Modulation of SH-SY5Y membrane microviscosity. A:
Membranes from SH-SY5Y cells were incubated with increasing
concentrations of CHS (circles) or (inset) with CHS (2.45
mmol/mg of protein) followed by increasing concentrations of
cis-vaccenic acid (squares). Following centrifugation, the mem-
branes were labeled with TMA-DPH (open symbols) or DPH
(solid symbols) and the anisotropy (r) of the samples was deter-
mined as described in Materials and Methods. Data are mean
6 SEM (bars) values of three experiments each carried out in
duplicate. *p , 0.01, significantly different from control mem-
branes. Inset: *p , 0.01, significantly different from 1 CHS
control membranes with no cis-vaccenic acid added; 1p , 0.01,
significantly different from 2 CHS control membranes indicated
in the main portion (circles). B: [3H]Sufentanil (0.1 nM ) binding
was evaluated in CHS-modified membranes in Tris-magnesium
buffer (E) or in the presence of 150 mM NaCl (F) or in the
presence of 150 mM NaCl and 1 mM GTPgS (h). *p , 0.01,
significantly different from control membranes with no CHS
added.
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through altered accessibility of ligand for them receptor
(“vertical displacement”).
To determine whether CHS rigidification of the mem-
brane alters the conformation of the receptor or alters its
interaction with G protein, the effects of CHS addition on
agonist binding were examined in membranes where G
proteins had been inactivated by the sulfhydryl reactive
agent NEM or by PTX pretreatment of cells. Because the
m-opioid receptor contains an NEM-sensitive sulfhydryl,
the alkylation reactions were done in the presence of
protecting concentrations of sodium and naltrexone (Si-
mon and Groth, 1975; Tocque et al., 1987). Under these
conditions, 2 h of NEM treatment reduced antagonist
([3H]naltrexone) binding by,20% but decreased agonist
([3H]DAMGO) binding by .80%, indicating that NEM
treatment uncoupled them receptor from G protein (data
not shown). In addition, low-Km GTPase basal activity
was reduced by 93%, and this activity was not increased
by incubation with agonist (data not shown). Addition of
CHS to NEM-treated membranes resulted in a fivefold
increase in [3H]sufentanil binding (Fig. 2B). That this
increase in binding was the result of a conversion of the
receptor to a high-affinity conformation was confirmed
by comparison of the dissociation of [3H]sufentanil in
NEM-treated membranes and those modified with CHS.
Bound [3H]sufentanil in NEM-treated membranes dis-
played both fast and slow components of dissociation
(site 1,k21 5 0.28 6 0.03 min
21, 52%; site 2,k21 5
0.016 6 0.002 min21, 44%), whereas in NEM-treated
membranes modified with CHS, [3H]sufentanil dissoci-
ation was best fit to a single slow dissociation rate
(0.00476 0.0014 min21). In PTX-treated membranes,
CHS addition (2.6mmol/mg of protein) resulted in in-
creased [3H]sufentanil (58 6 5%; Fig. 2C) and
[3H]DAMGO (61 6 2%) binding in the absence of
sodium and greatly attenuated the inhibitory effects of
sodium on agonist binding (data not shown). The greater
sensitivity to CHS in NEM-treated membranes when
compared with PTX-treated membranes likely results
from a lower level of functional G protein in the NEM-
treated membranes. This is supported by the greater
residual high-affinity [3H]sufentanil binding in the PTX-
treated membranes (3346 11 fmol/mg of protein) com-
pared with the NEM-treated membranes (546 6
fmol/mg of protein).
Although the binding of opioid agonists was increased
in membranes with reduced amounts of functional G
protein following CHS addition, the reduced effect of
sodium on agonist binding following CHS modification
appears to require the presence of a functional G protein.
At 2.5 mmol of CHS/mg of protein, a concentration that
completely suppressed the sodium effect in control mem-
branes (Figs. 1B and 2B), [3H]sufentanil binding was
still strongly reduced by sodium (265 6 5%) in NEM-
treated membranes (Fig. 2B). Even at levels of CHS two
times (4.6 mmol/mg of protein) that used in control
membranes, which resulted in a maximal increase of the
anisotropy at both the membrane surface and core, a
strong inhibition of agonist binding by sodium was still
observed (254 6 4%; data not shown). Similarly, PTX
pretreatment also reduced the effectiveness of CHS. In
control membranes, [3H]sufentanil binding was strongly
depressed by sodium and guanine nucleotide, and this
inhibition was reversed by CHS addition (Fig. 2C). Fol-
lowing PTX treatment, the strong inhibition of
[3H]sufentanil binding by sodium and guanine nucleotide
was partially reversed but remained statistically signifi-
cant (Fig. 2C). As indicated above, the observation that
CHS modification of PTX-pretreated membranes re-
duced the effectiveness of sodium and guanine nucleo-
tide to some degree may relate to the higher level of
residual G protein in these membranes as compared with
the NEM-treated membranes. No effect of CHS was
observed on [3H]naltrexone binding in either the absence
or presence of NaCl in PTX-treated membranes (data not
shown). These data suggest that a functional G protein is
necessary for the reduced effect of sodium on agonist
binding that is observed following CHS addition to the
membranes.
To determine if the effect of cholesterol was due to its
alteration of the membrane microviscosity or due to the
presence of a specific sterol–protein interaction, the abil-
ity of sodium and guanine nucleotide to inhibit sufentanil
binding was addressed following the reversal of mem-
brane fluidity. In membranes rigidified with CHS, addi-
tion of cis-vaccenic acid was found to reverse the rigidi-
fication of the membrane (Fig. 3). Reversal of the CHS-
induced increase in membrane microviscosity bycis-
vaccenic acid addition also restored the sensitivity of
agonist binding to ions and nucleotides (Fig. 3). NaCl
and GTPgS inhibited sufentanil (0.1 nM) binding in
control and CHS-modified membranes by 85 and 20%,
respectively. Subsequent addition ofcis-vaccenic acid to
the CHS-modified membranes increased the inhibition
FIG. 3. cis-Vaccenic acid reversal of the CHS effects on the
modulation of opioid agonist binding. In control membranes (E)
or those modified with CHS (2.45 mmol of CHS/mg of protein)
and increasing concentrations of cis-vaccenic acid (F), the bind-
ing of [3H]sufentanil (0.1 nM ) in the absence and presence of
NaCl (150 mM ) and GTPgS (10 mM ) was measured. Data are
mean 6 SEM (bars) values of percent inhibition of [3H]sufentanil
binding by NaCl and GTPgS from three experiments, each car-
ried out in duplicate. *p , 0.05, significantly different from the
absence of cis-vaccenic acid. Inset: Correlation of membrane
microviscosity in the membrane surface (F) and core (■) with the
inhibition of sufentanil binding caused by sodium and GTPgS.
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by sodium to that observed in control membranes (89%).
The respective decrease and restoration of the inhibition
of agonist binding most closely correlated with the
changes in TMA-DPH anisotropy (Fig. 3, inset). In con-
trast, addition ofcis-vaccenic acid to CHS-modified
membranes had little effect on antagonist ([3H]diprenor-
phine) binding. At a concentration ofcis-vaccenic acid
(0.542 mmol/mg of protein) that restored 60% of the
inhibition of [3H]sufentanil binding by sodium and
GTPgS, the binding of the antagonist was not signifi-
cantly altered (p 5 0.168, data not shown). At higher
concentrations ofcis-vaccenic acid, the binding of the
antagonist was reduced as previously reported (Remmers
et al., 1990). These data support the conclusion that
alterations in membrane fluidity and not a specific sterol–
protein interaction underlie the effects of CHS on opioid
binding.
Equilibrium saturation binding of antagonist and ago-
nist in CHS-modified membranes was performed to de-
termine if the changes in agonist binding seen in Figs. 1
and 2 were due to alterations in ligand binding affinity or
capacity. In the presence of NaCl, saturation binding of
the antagonists [3H]naltrexone and [3H]diprenorphine in
control membranes was characterized by a single satu-
rable site (Table 1). Addition of CHS (2.0mmol/mg of
protein) did not alter either the affinity or binding capac-
ity of [3H]naltrexone or [3H]diprenorphine (Table 1). In
addition, the apparent rate of dissociation of [3H]di-
prenorphine binding was similar in control (k21 5
0.0107 6 0.0002 min21) and CHS (2.2mmol/mg of
protein)-modified (k21 5 0.01156 0.0002 min
21; data
not shown) membranes. In contrast, addition of CHS to
membranes increased the number of high-affinity
[3H]sufentanil binding sites and strongly reduced the
inhibition by sodium and guanine nucleotide of agonist
high-affinity binding. Saturation binding of the agonist
[3H]sufentanil to SH-SY5Y cell membranes was charac-
terized by high binding affinity (28 pM) and capacity
(Table 1). We were unable to characterize accurately the
low-affinity [3H]sufentanil binding site. This component
was best described as a nonsaturating linear component
of the binding,Klin. Addition of NaCl reduced the high-
affinity binding capacity by 50% with no significant
change inKD. Further addition of both NaCl plus GTPgS
reduced the number of high-affinity binding sites by 88%
and decreased the affinity to 80 pM (Table 1), suggesting
a strong uncoupling of the receptor from G protein.
Addition of CHS to membranes increased the high-
affinity binding capacity of [3H]sufentanil by 28% with
little change in agonist affinity. The number of
[3H]sufentanil high-affinity binding sites in the presence
of CHS was similar to the total number ofm-opioid
receptors in the membrane preparation as determined by
saturation binding of them-opioid antagonist [3H]CTOP
(Table 1) (Hawkins et al., 1989). Also, in control mem-
branes, two [3H]sufentanil affinity states were indicated
by a biexponential dissociation of radioligand (site 1,k21
5 0.04 6 0.01 min21, 34%; site 2,k21 5 0.0027
6 0.0007 min21, 64%), whereas in CHS-modified mem-
branes, only the slowly dissociating component was ob-
served (0.00186 0.0001 min21; data not shown). Ad-
dition of NaCl to CHS-modified membranes reduced the
high-affinity binding (220.7%) to a lesser degree than
observed in control membranes (250.5%), and again no
change in affinity was observed. The further addition of
sodium plus guanine nucleotide to CHS-modified mem-
branes produced an additional small inhibition of the
high-affinity binding (225.1%) and also reduced the
affinity of sufentanil for the receptor, although not to the
extent observed in control membranes. Thus, addition of
CHS affected only agonist binding by reducing the so-
dium and GTPgS-induced uncoupling of the receptor
from G protein.
TABLE 1. Parameters of opioid binding in control and CHS-modified membranes





[3H]Sufentanil Control Tris 0.0286 0.001 6736 9
1 NaCl 0.0356 0.005 3336 28 1986 81
1 NaCl/GTPgS 0.086 0.02 786 18 3876 123
CHS (2.196 0.17) Tris 0.0396 0.002 8646 17
1 NaCl 0.0356 0.001 6856 16 1416 43
1 NaCl/GTPgS 0.0496 0.002 6476 23 2516 58
[3H]CTOPa Control Tris 0.2576 0.015 8576 24
[3H]Naltrexonea Control 1 NaCl 0.3456 0.007 6936 7
CHS (2.056 0.12) 1 NaCl 0.3276 0.01 6996 11
[3H]Diprenorphinea Control 1 NaCl 0.0956 0.004 5296 16
CHS (2.066 0.11) 1 NaCl 0.1016 0.005 5156 12
Ligand binding data were determined in control membranes and membranes modified with the concentration (mmol/mg of protein) of CHS indicated
as described in Materials and Methods. Where indicated, NaCl (150 mM) and GTPgS (10mM) were added to the Tris buffer (50 mM, pH 7.4). The
parameters shown were obtained from nonlinear regression analysis using the program SYSTAT using binding models with a single saturable binding
site, one site plus a nonsaturable linear component (Klin), or two saturable binding sites. The best fit was determined by theF-ratio test. Data are mean
6 SEM values from three experiments, each carried out in duplicate.
a [3H]CTOP parameters were determined in the same preparation of membranes used for the determination of [3H]sufentanil parameters.
[3H]Naltrexone and [3H]diprenorphine binding parameters were determined in a separate preparation of membranes.
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Opioid efficacy in control and CHS-modified
membranes
The effect of reduced membrane fluidity onm-opioid
receptor agonist efficacy was studied in membranes from
C6m cells. This cell line has previously been shown to
provide an excellent model system for the study of opi-
oid agonists of both high, e.g., DAMGO, and low, e.g.,
nalbuphine, efficacy due to the high level of opioid
receptors (10–20 pmol of receptor/mg of membrane pro-
tein) and opioid-stimulated [35S]GTPgS binding (Em-
merson et al., 1996). Agonist-sensitive conformational
changes in them-opioid receptor were studied by dis-
placement of [3H]naltrexone binding in both Tris-mag-
nesium buffer (TM buffer; high-affinity agonist binding)
and [35S]GTPgS binding “assay buffer” (with 100 mM
NaCl and 50mM GDP; low-affinity agonist binding).
Similar to SH-SY5Y cell membranes, agonist binding
affinity in C6m cell membranes was reduced by addition
of NaCl and GTPgS in a manner that correlated with
agonist efficacy (Table 2). Because sodium and guanine
nucleotides reduce DAMGO binding affinity to a greater
extent than that observed for sufentanil (Emmerson et al.,
1996), DAMGO was chosen to examine the effects of
CHS on binding and activation of G protein. Although
DAMGO binding affinity was strongly reduced, the af-
finity of nalbuphine was only weakly reduced by addi-
tion of sodium and GDP in the assay buffer (Fig. 4B and
Table 2). CHS (4mmol/mg of protein) addition to C6m
cell membranes had no effect on [3H]naltrexone binding
in either the absence or presence of sodium (data not
shown). Also, CHS addition did not alter the affinity of
either the full agonist DAMGO or the low-efficacy ago-
nist nalbuphine when assayed in TM buffer (Fig. 4 and
Table 2). As observed in SH-SY5Y cell membranes,
CHS addition to C6m cell membranes dramatically re-
duced the sensitivity of DAMGO binding to sodium and
GDP addition (Fig. 4A and Table 2). DAMGO binding
in the presence of sodium and GDP was best fit by a
two-site model. Addition of CHS was found to increase
slightly the fraction of high-affinity sites; however, the
affinity of both of the sites was increased by CHS addi-
tion. This is consistent with the results observed for
[3H]sufentanil (Table 1). The apparent effect of CHS was
to decrease the high-affinityBmax for [
3H]sufentanil.
Presumably the decrease inBmax for [
3H]sufentanil de-
scribed in Table 1 reflects a shift of receptors from high-
to low-affinity conformation, which is not well charac-
terized in a [3H]sufentanil saturation curve because the
affinity is so low. It is described by the linear component
Klin. Table 1 shows that the low-affinity [
3H]sufentanil
Klin component (1 Na/GTPgS) is smaller following
CHS addition and that the number of high-affinity sites is
approaching that for control membranes in Tris buffer.
Thus, the trend is similar in that both DAMGO and
sufentanil binding characteristics (1 CHS in sodium/
guanine nucleotide) approach those of control (Tris buff-
er). It is interesting that CHS had little effect on the
binding of nalbuphine in the presence of sodium and
GDP (Fig. 4B and Table 2), suggesting that the binding
of low-efficacy agonists to receptor are differentially
affected by lipid modifications.




TM buffer Assay buffer








K1 28.986 0.02 1.0 27.286 0.18 53 21.26 0.9 2406 19 (391%) 1.0
F1 0.466 0.10
K2 25.746 0.18 1,820
1 CHS
K1 28.806 0.01 1.6 28.106 0.06 7.9 4.96 0.2 133 6 5 (252%) 1.0
F1 0.666 0.11
K2 27.066 0.05 88
Nalbuphine
Control K1 29.066 0.01 0.9 28.216 0.01 6.2 1.706 0.04 14 6 3 (23%) 0.06
1 CHS K1 28.956 0.02 1.1 28.346 0.01 4.6 1.506 0.20 68 6 4 (129%) 0.51
Membranes were modified with CHS (4mmol/mg of protein) as described in Materials and Methods, and experiments were performed as described
in the legends to Figs. 4 and 5. The data were fit to one- and two-site competition curves, and anF-test (Graph Pad Prism) was used to determine
if the added site provided a significantly better fit of the data. The one-site fit was the best fit for all of the nalbuphine data sets and for the DAMGO
in Tris/magnesium (TM) buffer data. The DAMGO binding data in control and CHS membranes in GTPgS assay buffer (Assay buffer) were best
described by a two-site fit. F1 represents the fraction of high-affinity (K1) binding sites. Data are mean6 SEM (values) of three experiments, each
carried out in duplicate, presented as the increase in [35S]GTPgS binding relative to that in the absence of added ligand (61.31.6 and 52.76 0.5
fmol/mg of protein) in the absence and presence of CHS, respectively.
a Numbers in parentheses indicate the percent stimulation over basal [35S]GTPgS binding.
b Intrinsic activity is expressed as the fraction of stimulation relative to DAMGO.
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To evaluate the functional consequences of membrane
rigidification, agonist-mediated activation of G proteins
was quantified by measuring the agonist-induced in-
crease in the binding of [35S]GTPgS as well as by
GTPase activity. Although these assays measure G pro-
tein activation and G protein deactivation, respectively,
the relative agonist efficacy correlated with the direction
and degree of CHS modification in both assays. Both
assays indirectly reflect the ability of agonist-liganded
receptor to stimulate GDP dissociation from G protein.
DAMGO increased [35S]GTPgS binding by 240
fmol/mg of protein (391%), and that for nalbuphine was
increased by 14 fmol/mg of protein (23%). In CHS-
modified membranes, the potency of DAMGO to stim-
ulate nucleotide binding was strongly increased; how-
ever, the maximal stimulation was reduced by 45% (Fig.
5 and Table 2), suggesting a decrease in full agonist
efficacy. However, increased partial agonist efficacy was
observed in C6m cell membranes modified with CHS.
Following CHS addition, the maximal stimulation of
guanine nucleotide binding by nalbuphine was increased
almost fourfold (Fig. 5 and Table 2). Furthermore, stim-
ulation of low-Km GTPase activity by an additional se-
ries of partialm-opioid agonists was examined in control
and CHS-modified membranes (Fig. 5 and Table 3).
CHS addition increased the potency of the full agonist
DAMGO (7.3-fold) and the partial agonists meperidine
(6.4-fold) and profadol (3.8-fold) while leaving the po-
tency of the very weak partial agonist butorphanol unaf-
fected. Similar to the effect observed in the [35S]GTPgS
binding assay, the maximal stimulation for DAMGO
was reduced, whereas the efficacies of all three partial
agonists were significantly increased compared with
DAMGO (Fig. 6 and Table 3). These data suggest that
the effect of CHS on opioid receptor–G protein coupling
was dependent on the efficacy of the opioid tested.
DISCUSSION
The results described here show that membrane rigidi-
fication (in both SH-SY5Y and C6m cell membranes)
results in agonist-specific alterations in ligand binding as
well as a significant increase in partial agonist efficacy.
These findings suggest that membrane rigidification sta-
bilizes the G protein-coupled form of them-opioid re-
ceptor. These findings further extend those by our labo-
ratory (Lazar and Medzihradsky, 1993) and others (Her-
on et al., 1981) to show that modulation of opioid
receptor function by the lipid bilayer involves effects not
only on the binding of ligands to the receptor but also on
the coupling of the receptor to G protein. The following
equation is a general model of agonist binding and sub-
sequent G protein activation on which we base our dis-
cussion of the potential modulatory mechanisms of
membrane microviscosity:
FIG. 4. Agonist displacement of [3H]naltrexone in control and
CHS-modified membranes. Control membranes (circles) or
those modified with CHS (squares; 4 mmol/mg of protein) were
incubated with [3H]naltrexone (0.5 nM ) and various concentra-
tions of (A) DAMGO or (B) nalbuphine in Tris-magnesium buffer
(control; open symbols) or assay buffer (Na/GDP; solid symbols)
for 2 h at 25°C. The curves are a result of nonlinear least-squares
fit to a model of either one or two binding sites as described in
Materials and Methods. Data are mean 6 SEM (bars) values
from three experiments, each carried out in duplicate. The IC50
values and SEM are shown in Table 2.
FIG. 5. Agonist stimulation of [35S]GTPgS binding in control and
CHS-modified membranes. Stimulation of [35S]GTPgS binding
by (A) DAMGO and (B) nalbuphine was examined in control
membranes (E) or those modified with CHS (F; 4 mmol/mg of
protein) as described in Materials and Methods. [35S]GTPgS
binding in the absence of ligand was 61.3 6 1.6 and 52.7 6 0.5
fmol/mg of protein in control and CHS-modified membranes,
respectively. Data are mean 6 SEM (bars) values of percent
stimulation of [35S]GTPgS binding over that in the absence of
added ligand from three experiments, each carried out in dupli-
cate. Results of sigmoidal dose–response curve fitting are listed
in Table 2.
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L 1 R º
Step 1






In step 1, ligand (L) binds to receptor (R) to form
activated ligand–receptor complex LR*. Step 2 indi-
cates the binding of LR* to heterotrimeric G protein
(G). Step 3 indicates G protein activation (G*), which
includes the exchange of GDP for GTP. Because basal
GTPgS binding does not change significantly in CHS-
modified membranes, activated unliganded receptor
(R*) was not included in the model. These data sug-
gest that all three steps are affected by decreased
membrane fluidity.
Ligand binding in the presence of functional G
protein (steps 1 and 2)
Addition of CHS to SH-SY5Y and C6m cell mem-
branes was found to alter selectively the regulation of
opioid agonist binding by sodium and guanine nucleo-
tides. CHS incorporation strongly and maximally in-
creased the microviscosity of SH-SY5Y membranes
without affecting the binding of two opioid antagonists,
[3H]naltrexone and [3H]diprenorphine, or the protein
content of these membranes even at very high levels of
CHS incorporation. However, the modulation of opioid
agonist binding by sodium and guanine nucleotide was
strongly reduced by the increase in membrane microvis-
cosity. In contrast to the findings of Heron et al. (1981),
the effects of CHS were agonist-specific and did not
result in a loss in receptor binding (“shedding”) or mem-
brane protein content even at high CHS concentrations,
indicating that CHS does not modulate the accessibility
of ligand for the receptor as suggested by a vertical
displacement model of CHS action. These specific ef-
fects on agonist binding may result from (a) direct lipid–
receptor interaction, (b) alteration in conformational
flexibility of the receptor through increased microviscos-
ity (step 1), or (c) microviscosity effects on receptor–G
protein interactions (step 2). The reversibility of the
effects of CHS by membrane fluidizers suggests that a
direct lipid–receptor interaction is not likely. Second, as
observed in TM buffer, the ability of CHS to increase
agonist binding in the absence of functional G protein
(step 1 in Eq. 1) indicates that microviscosity, in addition
to G protein, can modulate the agonist-bound receptor
conformation. Third, there appears to be a complex in-
teraction among changes in membrane microviscosity,
the ability of G protein to stabilize high-affinity agonist
binding (step 2), and the observed increase in agonist
efficacy.
TABLE 3. Stimulation of GTPase activity in control and CHS-modified C6m cell membranes
Ligand
EC50 (nM) (95% CI) Efficacy
a
Control 1 CHS Control 1 CHS
DAMGO 80 (29–212) 11 (4–26)b 1.0 1.0
Meperidine 14,120 (9,984–19,960) 2,200 (1,369–3,535)b 0.436 0.02 0.746 0.04b
Profadol 295 (135–648) 78 (60–102)b 0.296 0.01 0.746 0.04b
Butorphanol 0.8 (0.2–3) 2 (1–5) 0.086 0.01 0.466 0.08b
Membranes were prepared from C6m cells, control or modified with CHS, and agonist-stimulated GTPase
activity was measured as described in Materials and Methods. Data from two experiments were combined and
fit to a sigmoidal dose–response equation. EC50 values are mean values (95% confidence interval), and efficacy
values are mean6 SEM values. Unpaired, two-tailedt tests were performed using Graph Pad Prism, comparing
the log(EC50) or efficacy, SE, and the number of points for control and treated membranes.
a The efficacy for each ligand is relative to that of DAMGO, where DAMGO efficacy in both control and
CHS-modified membranes is defined as 1.0. DAMGO efficacy in CHS-modified membranes is 0.576 .04
relative to that of DAMGO in control membranes.
b p , 0.05, significant difference between EC50 or efficacy values from control and CHS-treated membranes.
FIG. 6. Agonist-stimulated GTPase activity in control and CHS-
modified membranes. GTPase activity stimulated by (A) DAMGO
and (B) butorphanol in control and CHS-modified membranes
was measured as described in Materials and Methods. Shown is
the best fit of a sigmoidal dose–response curve for representa-
tive experiments performed in duplicate that were repeated.
Average EC50 values and relative efficacies for these and two
additional agonists are shown in Table 3.
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The molecular consequence of sodium binding to the
opioid receptor was suggested to be a conformational
change from an “agonist-favoring” to an “antagonist-
favoring” state (Simon and Groth, 1975; Simon and
Hiller, 1981), although in the present study this simple
conformational model does not fully explain the ob-
served changes in receptor binding because agonist bind-
ing was strongly modulated by sodium, whereas antag-
onist binding was unaffected. The presence of a G pro-
tein has been shown to be required for the stabilization of
the high-affinity opioid agonist binding (Remmers and
Medzihradsky, 1991a). In the absence of G protein, the
receptor exists in a conformation with low affinity for
ligand. Based on the suggestion that membrane micro-
viscosity can modulate the conversion of integral mem-
brane proteins between conformational states (Swann,
1984; Yeagle, 1991; Mitchell et al., 1992), we postulated
that the interaction of them-opioid receptor with G
protein and the conformational change resulting in the
conversion of receptor between agonist high- and low-
affinity states may be modulated by addition of CHS. In
the absence of sodium, addition of CHS rigidified the cell
membrane and increased agonist binding, resulting in the
formation of a single agonist high-affinity conformation
of the receptor as indicated by a single slowly dissociat-
ing binding component. The conversion of the receptor
to a single affinity state is also supported by the close
agreement between the number of high-affinity agonist
binding sites in the presence of CHS and the total num-
ber of m-opioid binding sites in this preparation deter-
mined by the antagonist [3H]CTOP. These findings sug-
gest that under some conditions, the conformation of the
m receptor may be directly modulated by its lipid envi-
ronment.
Ligand binding in the absence of functional G
protein (step 1)
In membranes where G protein had been inactivated,
addition of CHS greatly enhanced the binding of agonist
to the free receptor (Fig. 2B), indicating a conversion of
the receptor to a higher-affinity conformation. Similarly,
low temperature-induced conversion of thea1-adrener-
gic receptor to a single agonist high-affinity state was not
dependent on the presence of a G protein (Lynch et al.,
1988). Rigidification of the membrane bilayer or low
temperature may create a condition in the lipid surround-
ing the receptor where increased lateral pressure (Yeagle,
1991) directly alters the equilibrium between low- and
high-affinity receptor conformations, leading to the sta-
bilization of a G protein-independent agonist high-affin-
ity state. However, in G protein-free membranes after
CHS modification, the rate of [3H]sufentanil dissociation
remained faster (t1/2 5 147 min) than observed in control
membranes after CHS addition (t1/2 5 384 min), indi-
cating that these receptor conformations may not be
identical. Increased membrane microviscosity may in-
completely alter receptor conformation either owing to
its indirect effects on the receptor or owing to the stabi-
lization of an intermediate conformation of the receptor,
which may then be converted by G protein to the high-
affinity state. In fact, mutation of theb-adrenergic recep-
tor stabilizes a receptor conformation with intermediate
agonist binding affinity (Samama et al., 1993), suggest-
ing that G protein-linked receptors may exist in multiple
conformations with agonist, G protein, and possibly the
membrane environment, affecting the equilibrium be-
tween these states.
In membranes where G protein was inactivated, CHS
no longer completely reduced the inhibitory effect of
sodium and guanine nucleotide on agonist binding.
These data suggest that increased microviscosity alone is
not sufficient to stabilize the receptor in a high-affinity
sodium and guanine nucleotide-insensitive conforma-
tional state. Therefore, the effects of CHS and reduced
membrane fluidity likely require the presence of a func-
tional G protein to attenuate the effects of sodium on
agonist binding. In these experiments, membranes were
modified with CHS before addition of sodium and gua-
nine nucleotides. Under these conditions, receptor and G
protein are known to be precoupled (Graeser and Neubig,
1993; Tian et al., 1994). Thus, rigidification of the mem-
brane may stabilize the receptor–G protein complex by
either inhibiting its dissociation or enhancing its forma-
tion. Examination of the affinity states of the purified and
reconstitutedm-opioid receptor may be required to define
unequivocally the role of membrane microviscosity on
opioid receptor affinity states and G protein coupling.
Agonist efficacy (steps 2 and 3)
Agonist efficacy has been characterized by the affinity
of ligand-bound receptor LR for G protein (step 2) (Tota
and Schimerlik, 1990) as well as the ability to dissociate
GDP from the G protein leading to subsequent GTP
binding (step 3) (Lorenzen et al., 1996). In addition to the
observed effects of membrane rigidification on the affin-
ity of agonist for receptor, CHS appears to stabilize the
LRG complex and thus increase agonist potency. Clarke
and Bond (1998) suggested that intrinsic efficacy may be
dependent on the biological system in which the assay is
performed. They proposed that the probability of a cer-
tain receptor conformation might be influenced by the
microenvironment of the protein. The data showing in-
creased partial agonist efficacy in rigidified membranes
support this hypothesis. However, in these experiments,
we did not evaluate the possibility that CHS may also
decrease GDP affinity for G protein, thus allowing for
the more rapid binding of GTPgS (step 3). The observed
decrease in maximal DAMGO-stimulated GTPgS bind-
ing in CHS-modified membranes may be due to reduced
membrane diffusion of receptor to additional G protein,
reduced agonist switching (Stickle and Barber, 1991;
Mahama and Linderman, 1994) due to slower agonist
dissociation rates, or a decrease in the number of G
proteins able to couple functionally to receptors due to
potential alterations in membrane domains.
The possibility exists that CHS exerts its effects not
only through alterations of membrane fluidity but also
through alteration of membrane lipid domains. Due to
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the lack of correlation between changes in microviscos-
ity and the function of integral membrane proteins, re-
organization of membrane lipid domains has also been
suggested as a mechanism for alterations induced by
lipid addition (Carruthers and Melchior, 1986). In addi-
tion to previously described caveolae and clathrin-coated
pits, membrane subdomains enriched in sphingolipid and
cholesterol have been shown to form detergent-insoluble
ordered domains (Schroeder et al., 1998). Recent evi-
dence (Feder et al., 1996; Holowka and Baird, 1996;
Fielding and Fielding, 1997) suggests that the antigen-
mediated immunoglobulin receptor activation process
involves the interaction of aggregated high-affinity IgE
receptor with specialized plasma membrane domains that
may localize important signaling molecules in the vicin-
ity of aggregated receptors. Although these various stud-
ies were aimed toward understanding the operation of
one cell surface receptor, they provide new insights into
plasma membrane structure and dynamics. Except for the
immunoglobulin complex formation and the requirement
for receptor internalization, the significance of mem-
brane subdomains on receptor–effector interaction is
largely unknown. The stabilization of membrane subdo-
mains by CHS addition could potentially account for the
increased efficacy of partial agonists observed here. Our
experiments do not distinguish between gross or subdo-
main changes in membrane microviscosity, and therefore
we can only hypothesize on the molecular mechanisms
of increased G protein activation.
The possibility of membrane subdomains does not
diminish the observation that changes in membrane bio-
physical properties correlate with changes in opioid re-
ceptor binding. The actions of CHS (Lazar and Medzi-
hradsky, 1993) and fatty acid isomers (Remmers et al.,
1990; Lazar and Medzihradsky, 1992) were suggested to
modulate opioid receptor binding in a manner correlated
with changes in microviscosity. In SH-SY5Y mem-
branes, a close correlation between CHS rigidification of
membranes and reversal bycis-vaccenic acid and the
reduction and restoration of opioid agonist modulation
by sodium and guanine nucleotide supports the conclu-
sion that the observed effects are mediated by changes in
the membrane biophysical properties. The fact thatcis-
vaccenic acid could restore both surface membrane flu-
idity and agonist binding to control levels in CHS-mod-
ified membranes and the close correlation between mem-
brane surface fluidity and agonist binding suggest that
the phosphate head group region of the membrane may
be most influential in the regulation of agonist binding in
the presence of sodium and guanine nucleotide.
These effects indicate that the lipid bilayer is a regu-
lator of opioid receptor binding and signal transduction.
The changes in membrane composition and biophysical
properties resulting from diet (McMurchie, 1988), age
(Gurdal et al., 1995), and pathophysiological states (Ra-
ber and Bast, 1989; Ma et al., 1994; Roth et al., 1995)
suggest a significant regulatory role for the membrane
bilayer in cellular signal transduction. The use of newly
developed fluorescently labeled opioids (Emmerson et
al., 1997) will allow the further examination of the
interaction between the lipid bilayer and the opioid re-
ceptor.
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